Targeting TIGIT: Understanding New Approaches for Inhibiting the Immune Checkpoint Pathway

In this episode, Jyoti D. Patel, MD, and Diwakar Davar, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising early-phase clinical trial results. The episode includes a comprehensive explanation of TIGIT, how the TIGIT pathway functions, and the potential role of TIGIT inhibition for the treatment of cancer, including analyses from ongoing clinical trials such as CITYSCAPE, PACIFIC-8, ARC-7, and SKYSCRAPER-01.Presenters:Jyoti D. Patel, MDProfessor of MedicineDivision of Hematology and OncologyMedical Director for Thoracic OncologyAssistant Director for Clinical ResearchAssociate Vice Chair of Clinical ResearchDepartment of MedicineRobert H. Lurie Comprehensive Cancer CenterNorthwestern UniversityChicago, IllinoisDiwakar Davar, MDAssistant Professor, Melanoma and Phase I TherapeuticsDivision of Hematology/OncologyDepartment of MedicineUniversity of Pittsburgh Hillman Cancer CenterPittsburgh, PennsylvaniaLink to the complete program, including an online text module with downloadable slidesets, ClinicalThought commentaries, and an additional podcast on this topic:https://bit.ly/3r9BLmB